Macmillan Digital Science, part of Macmillan Publishers, backs the independent review website for antibodies and life science products, in its second round.
Macmillan Digital Science, a technology business for researchers, which is part of Macmillan Publishers, has helped 1DegreeBio, an independent review website for antibodies and life science products, raise a series B round.
Philip Armstrong, chief executive of Jovian Capital Corporation, and 1DegreeBio senior management also participated in the round.
Digital Science’s other portfolio companies include SureChem, Labtiva, BioData, BioRAFT, figshare and Symplectic.
1DegreeBio has increased its user base from 23,000 to more than 75,000 users, and increased its product…
